exenatide extended-release

DRUG2 trials

Sponsors

OPKO Health, Inc., Sanofi

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes Mellitus

Phase 2

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

CompletedNCT02119819

OPKO Health, Inc.Diabetes Mellitus, Type 2

Start: 2014-04-30End: 2015-10-31Updated: 2021-05-27

Phase 3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

CompletedNCT02787551

SanofiType 2 Diabetes Mellitus

Start: 2016-07-06End: 2018-11-17Updated: 2022-03-25

Related Papers

Fixed‐ratio combination of insulin glargine plus lixisenatide ( <scp>iGlarLixi</scp> ) improves ß‐cell function in people with type 2 diabetes

Diabetes Obesity and Metabolism2022-03-0812 citations

Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.

2021-12-116 citations

88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting

Diabetes2020-06-011 citations

149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)

Diabetes2019-06-011 citations

1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)

Diabetes2019-06-011 citations

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

Diabetes2019-06-01